Drug Approval | November 20, 2023
Teva announces approval of a generic version of Forteo in US
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
European operations' revenue grew 58.4% to Rs 599.7 crore
The collaboration brings a seamless digital experience to more formulators worldwide
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
The companies plan to start a pivotal Phase 3 trial in the coming months
Additional premium services in RegXcellence will include access to BASF’s Product Carbon Footprint data and direct downloads of audit reports
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Subscribe To Our Newsletter & Stay Updated
